Compare EVO & MASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | MASS |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 568.6M | 498.1M |
| IPO Year | 2007 | 2020 |
| Metric | EVO | MASS |
|---|---|---|
| Price | $1.59 | $9.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $4.48 | ★ $14.00 |
| AVG Volume (30 Days) | 65.9K | ★ 365.2K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 125.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $56,197,000.00 |
| Revenue This Year | N/A | $23.13 |
| Revenue Next Year | $18.90 | $18.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.33 | $5.03 |
| 52 Week High | $3.87 | $13.35 |
| Indicator | EVO | MASS |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 40.13 |
| Support Level | $1.50 | $9.32 |
| Resistance Level | $1.61 | $10.88 |
| Average True Range (ATR) | 0.06 | 0.93 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 28.13 | 12.84 |
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
908 Devices Inc develops a suite of purpose-built handheld devices for point-of-need chemical analysis. Leveraging mass spectrometry, optical spectroscopy, analytics and machine learning technologies, the company makes devices that are smaller and more accessible than conventional laboratory instruments. Its devices, including MX908, ThreatID, XplorIR and VipIR, are used to analyze unknown materials and provide actionable answers in health, safety and defense technology applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure and security threats. The company reimagines mass spectrometry technology by developing smaller, lower-cost and simpler-to-operate devices compared to conventional instruments, and generates maximum revenue from the United States.